Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review
Vipawee S. Chat
Medical College of Georgia, Augusta University, Augusta, Georgia, USA
Search for more papers by this authorDonovan G. Kearns
Loma Linda University School of Medicine, Loma Linda, California, USA
Search for more papers by this authorCorresponding Author
Jashin J. Wu
Dermatology Research and Education Foundation, Irvine, California, USA
Correspondence
Jashin J. Wu, Dermatology Research and Education Foundation, Irvine, CA, USA.
Email: [email protected]
Search for more papers by this authorVipawee S. Chat
Medical College of Georgia, Augusta University, Augusta, Georgia, USA
Search for more papers by this authorDonovan G. Kearns
Loma Linda University School of Medicine, Loma Linda, California, USA
Search for more papers by this authorCorresponding Author
Jashin J. Wu
Dermatology Research and Education Foundation, Irvine, California, USA
Correspondence
Jashin J. Wu, Dermatology Research and Education Foundation, Irvine, CA, USA.
Email: [email protected]
Search for more papers by this authorAbstract
The aim of this review is to compare and contrast evidence-based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Clinical practice guidelines from the American Academy of Dermatology, National Psoriasis Foundation, British Association of Dermatologists, and European S3 were reviewed and compared. Practice guidelines from the three dermatological organizations are similar with regards to treatment dosage and initiation but differ in their recommendations for baseline screening and interval laboratory monitoring, treatment in patients undergoing surgery or receiving live vaccines, and treatment contraindications. Ustekinumab is an effective and well-tolerated systemic treatment for patients with psoriasis and should be considered in the line of therapy that dermatologists discuss with their patients. Consideration should be given to evidence-based practice guidelines of global dermatology organizations to effectively guide treatment decisions in patients with psoriasis.
CONFLICT OF INTEREST
Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dr. Reddy's Laboratories, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
REFERENCES
- 1Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017; 31(2): 205-212.
- 2Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/north American dermatology clinics. J Am Acad Dermatol. 2013; 69(5): 729-735.
- 3Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010; 90(2): 147-151.
- 4Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009; 23(5): 561-565.
- 5Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017; 76(3): 377-390.
- 6 Janssen Pharmaceutical Companies of Johnson & Johnson. U.S. Food and Drug Administration Approves STELARA® (ustekinumab) for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis. https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-stelara-ustekinumab-for-treatment-of-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-301103505.html. Published July 30, 2020. Accessed August 6, 2020.
- 7Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019; 80(4): 1073-1113.
- 8Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019; 80(4): 1029-1072.
- 9Nast A, Spuls PI, van der Kraaij G, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris - update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017; 31(12): 1951-1963.
- 10Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris–update 2015–short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015; 29(12): 2277-2294.
- 11Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update - short version part 1 - systemic treatment. J Dtsch Dermatol Ges. 2018; 16(5): 645-669.
- 12Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017; 177(3): 628-636.
- 13Smith CH, Yiu ZZ, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update. Br J Dermatol. 2020; 183(4): 628-637.
- 14Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009; 161(5): 987-1019.
- 15Brodmerkel C, Wadman E, Langley RG, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013; 12(10): 1122-1129.
- 16Brodmerkel C, Zhu Y, Jiao Q, et al. Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. J Drugs Dermatol. 2010; 9(6): 677-683.
- 17 British Association of Dermatologists - Patient Information Leaflets (PILs) [Internet]. London (UK): British Association of Dermatologists; c2010-2019, updated 2019 February; cited September 14, 2020. https://www.bad.org.uk/patient-information-leaflets/ustekinumab/
- 18Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014; 73(6): 1000.
- 19Kavanaugh A, Menter A, Mendelsohn A, et al. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin. 2010; 26(10): 2385-2392.
- 20Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373(9664): 633-640.
- 21McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382(9894): 780-789.
- 22Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol. 2012; 166(1): 147-153.
- 23Rich P, Bourcier M, Sofen H, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatology. 2014; 170(2): 398-407.
- 24Rigopoulos D, Gregoriou S, Makris M, et al. Efficacy of Ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with Ustekinumab for cutaneous psoriasis: an open prospective Unblinded study. Dermatology. 2011; 223(4): 325-329.
- 25Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatol Treat. 2013; 24(2): 96-100.
- 26Papadavid E, Ferra D, Koumaki D, et al. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic. Dermatology. 2014; 228(2): 107-111.
- 27Levin EC, Debbaneh M, Koo J, et al. Biologic therapy in erythrodermic and pustular psoriasis. J Drugs Dermatol. 2014; 13(3): 342-354.
- 28Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012; 167(2): 417-423.
- 29Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010; 163(5): 1116-1118.
- 30Au S-C, Goldminz AM, Kim N, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatol Treat. 2013; 24(3): 179-187.
- 31Buder V, Herberger K, Jacobi A, et al. Ustekinumab in the treatment of palmoplantar pustular psoriasis – a case series of nine patients. JDDG: J Deutschen Dermatol Gesellschaft. 2016; 14(11): 1108-1113.
- 32Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol. 2013; 168(4): 820-824.
- 33Bulai Livideanu C, Lahfa M, Mazereeuw-Hautier J, et al. Efficacy of Ustekinumab in palmoplantar psoriasis. Dermatology. 2010; 221(4): 321-323.
- 34Vittorio Luigi De Socio G, Simonetti S, Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis. 2006; 38(1): 74-75.
- 35Chiricozzi A, Saraceno R, Cannizzaro MV, et al. Complete resolution of Erythrodermic psoriasis in an HIV and HCV patient unresponsive to Antipsoriatic treatments after highly active antiretroviral therapy (ritonavir, Atazanavir, Emtricitabine, Tenofovir). Dermatology. 2012; 225(4): 333-337.
- 36Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013; 169(6): 1295-1303.
- 37Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013; 168(3): 609-616.
- 38Choi YM, Debbaneh M, Weinberg JM, et al. From the medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2016; 75(4):798–805.e7.
- 39 Stelara|European Medicines Agency [Internet]. Amsterdam (NL): European Medicines Agency; c2009-2020, updated 2020 February 25; cited September 14, 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/stelara#product-information-section
